Compare ZJYL & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZJYL | ECOR |
|---|---|---|
| Founded | 2006 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.5M | 39.6M |
| IPO Year | 2023 | 2018 |
| Metric | ZJYL | ECOR |
|---|---|---|
| Price | $0.21 | $4.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $25.50 |
| AVG Volume (30 Days) | ★ 156.6K | 33.0K |
| Earning Date | 08-20-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | $22,826,624.00 | ★ $29,835,000.00 |
| Revenue This Year | N/A | $28.61 |
| Revenue Next Year | N/A | $41.21 |
| P/E Ratio | $19.28 | ★ N/A |
| Revenue Growth | 13.42 | ★ 27.90 |
| 52 Week Low | $0.22 | $4.16 |
| 52 Week High | $1.42 | $19.49 |
| Indicator | ZJYL | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 26.13 | 45.38 |
| Support Level | $0.23 | $4.75 |
| Resistance Level | $0.28 | $5.09 |
| Average True Range (ATR) | 0.02 | 0.20 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.27 | 21.95 |
Jin Medical International Ltd offers rehabilitation equipment. It is engaged in the design, development, manufacturing, and sales of wheelchairs and other living aids products to be used by people with disabilities or impaired mobility. The company's products are sold to distributors in both China and overseas markets. Its product offerings comprise Wheelechaire serirs, Bath products, oxygen machines, and nursing products. Geographically, it generates the majority of its revenue from Japan.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.